Latest Shareholder Approval News

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

United States Antimony Corporation has proposed acquiring Larvotto Resources in a deal that could create one of the largest antimony producers outside China, offering Larvotto shareholders a significant premium.

Southern Palladium has raised A$20 million through a strategic share placement to accelerate its Bengwenyama PGM project, positioning the company for key milestones including a Final Investment Decision in 2026.

Jindalee Lithium has launched an options offer linked to its recent Share Purchase Plan and placements, aiming to incentivize shareholders and raise capital for its lithium development projects. The options carry an exercise price of $0.825 and expire in late 2028.

Jindalee Lithium has successfully raised $8 million through a private placement, complemented by a $1 million Share Purchase Plan, to advance its McDermitt Lithium Project and a strategic US SPAC transaction.

European Lithium Limited has launched a replacement options offer for holders of 205 million expiring options, with directors committing to fully participate and underwrite the offer pending shareholder approval at the upcoming AGM.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Australian Strategic Materials secures A$50.8 million via share placement to fund Korean plant expansion and advance US metals project, while navigating complex supply chain and funding risks.

ASM Limited has raised A$55 million to accelerate production capacity at its Korean Metals Plant and expand its footprint in the rare earths sector, responding to growing global demand and geopolitical supply chain pressures.

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.